Market Intelligence

Access the latest earnings reports, market analysis, hot topics, and individual stock insights

Report Categories

View All

Recent Articles

View All
UK Childcare Costs Threaten Family Affordability Government Warns Indonesian Commodity Exporters Raise Concerns Over Proposed State Monopoly HP Exceeds Estimates on AI PC and Windows 11 Demand Shares Initially Surge American Express National Bank Review HighYield Accounts Without Overdraft or Monthly Fees AI Demand Drives Supply Constraints for Lasers Fiber Optics and Optical Components MBX Biosciences Inc MBX Q1 2026 Earnings EPS Beat as PreRevenue Biotech Advances Pipeline KR Q1 2026 Earnings Kroger Beats EPS Estimates Amid Solid Execution Centuri Holdings Inc CTRI Q1 2026 Earnings NarrowerthanExpected Loss Drives Positive Market Response Protara Therapeutics Q1 2026 Earnings EPS Beat Despite No Revenue Stock Declines RPM Q1 2026 Earnings Massive EPS Beat Drives Stock Higher Anteris Technologies Global Corp AVR Surges 489 Key Levels to Watch DexCom DXCM Pulls Back 243 as Stock Approaches Key Support Level YDKG Shows Signs of Life Yueda Digital Holding Gains 322 as Support Holds YXTCOM Group Holding Limited YXT Edges Higher on Modest Buying Testing Key Resistance Major League Pickleball Season Opens in Dallas as Los Angeles Mad Drops Secure Victory Air India to Reduce Domestic Flight Frequencies by Over 20 Amid Rising Fuel Costs Microsofts New Trusted Tech Lead Tackles AI Speed vs Responsibility Challenge TrumpXi Summit Yields Deals on Soybeans and Rare Earths China Signals Potential Tariff Cuts Bhatia Communications Shares Climb 3 on Strong Q4 Earnings Amid Broader Market Weakness DeepSeek AI Chinese Startup Claims CostEffective Model Training Without Advanced Chips Indian Equity Markets Edge Lower as Geopolitical Tensions Rise Midcaps Outperform Broader Indexes India PM Urges WholeofNation Approach to Mitigate Heatwave Impact on Economy and Public Health Microsoft Appoints New Trusted Technology Lead to Balance AI Speed with Responsible Development Citius Pharmaceuticals Gains Analyst Attention with Potential 843 Upside on LYMPHIR Approval